尿激酶型纤溶酶原激活物在乳腺癌中的表达及意义  

Expression and significance of urokinase type plasminogen activator in breast cancer

作　　者：肖继平[1] 张广德[1] 夏文华[1] 陈德基[2] 

机构地区：[1]湖北医科大学附属第二医院肿瘤科,武汉430071 [2]湖北医科大学病理科

出　　处：《中华肿瘤杂志》1999年第3期196-198,共3页Chinese Journal of Oncology

摘　　要：目的　研究尿激酶型纤溶酶原激活物（ｕｒｏｋｉｎａｓｅｔｙｐｅ ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ，ｕＰＡ） 在乳腺癌组织中的表达及其临床意义。方法　应用免疫组化ＳＡＢＣ法检测１００ 例原发性乳腺癌患者中的ｕＰＡ的表达。结果　１００ 例乳腺癌患者中，ｕＰＡ高表达５５ 例，占５５０ ％ ；低表达者４５ 例，占４５０％ 。ｕＰＡ表达与ＴＮＭ 分期、淋巴结状况及肿瘤大小相关，与年龄、月经状况、ＥＲ 无关。ｕＰＡ 高表达者的无病生存期和总生存期低于ｕＰＡ 低表达者。单因素分析显示，ｕＰＡ 的预后作用与淋巴结状况和ＴＮＭ 分期相似，但比ＥＲ、肿瘤大小要强。多因素分析显示，ｕＰＡ是影响无病生存期和总生存期的一个独立预后因子。Objective To study the expression and clinical significance of urokinase type plasminogen activator (uPA) in breast cancer.Methods Applying streptavidin biotin complex (SABC) immunohistochemical technique, expression of uPA was studied in 100 patients with primary breast cancer.Results There were 55 patients with high uPA expression, and 45 with low expression. There was significant correlation between uPA expression and TNM stage, lymph node status, tumor size. Neither age, menopausal status, nor ER status was significantly related with level of uPA expression Patients with high expression of uPA had significantly shorter disease free survival period and overall survival than did those with low expression of uPA. Univariate analysis showed that uPA as a prognostic factor was of similar magnitude to lymph node status and TNM stage, but stronger than that of ER status and tumor size. uPA was an independent prognostic factor affecting disease free survival and overall survival.Conclusion uPA appears to be a strong and independent biolgic marker for predicting prognosis of breast cancer.

关 键 词：乳腺癌 UPA 表达 免疫组织化学 预后 

分 类 号：R737.9[医药卫生—肿瘤]